Literature DB >> 23100351

Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum.

Claudio Piersimoni1, Alessandro Mustazzolu, Federico Giannoni, Stefano Bornigia, Giancarlo Gherardi, Lanfranco Fattorini.   

Abstract

The susceptibility of 211 clinical isolates of Mycobacterium tuberculosis complex (201 M. tuberculosis and 10 Mycobacterium bovis isolates) to pyrazinamide (PZA) was assessed by the nonradiometric Bactec MGIT 960 system (M960). Detection of PZA resistance was followed by a repeat testing using a reduced inoculum (RI) of 0.25 ml instead of 0.5 ml. According to the first M960 analysis, resistance was observed in 55 samples. In the RI assay, 32 samples turned out to be susceptible and 23 proved to be resistant (58.2% false positivity). The Bactec 460 assay confirmed as resistant those strains detected by the RI assay, while discrepant results were found susceptible. Mutation analysis performed on 13 M. tuberculosis isolates detected pncA mutations in 11 samples. On the basis of our data, we suggest using the RI assay to confirm all PZA resistance results obtained with the standard M960 assay. Further studies are required to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23100351      PMCID: PMC3536208          DOI: 10.1128/JCM.01838-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  M Mestdagh; P A Fonteyne; L Realini; R Rossau; G Jannes; W Mijs; K A De Smet; F Portaels; E Van den Eeckhout
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Treatment of tuberculosis: update 2010.

Authors:  W W Yew; C Lange; C C Leung
Journal:  Eur Respir J       Date:  2010-09-16       Impact factor: 16.671

3.  Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Pamela Chedore; Lina Bertucci; Joyce Wolfe; Meenu Sharma; Frances Jamieson
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

Review 4.  Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

Authors:  Kwok Chiu Chang; Wing Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

5.  Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay.

Authors:  M A Miller; L Thibert; F Desjardins; S H Siddiqi; A Dascal
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

6.  Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand.

Authors:  Sushil Pandey; Sandie Newton; Arlo Upton; Sally Roberts; Dragana Drinković
Journal:  Pathology       Date:  2009       Impact factor: 5.306

7.  Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains.

Authors:  Jun-Ichiro Sekiguchi; Tomohiko Nakamura; Tohru Miyoshi-Akiyama; Fumiko Kirikae; Intetsu Kobayashi; Ewa Augustynowicz-Kopec; Zofia Zwolska; Koji Morita; Toshinori Suetake; Hiroshi Yoshida; Seiya Kato; Toru Mori; Teruo Kirikae
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

8.  Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  K Hirano; M Takahashi; Y Kazumi; Y Fukasawa; C Abe
Journal:  Tuber Lung Dis       Date:  1997

9.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

10.  Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis.

Authors:  Pontus Juréen; Jim Werngren; Juan-Carlos Toro; Sven Hoffner
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

View more
  26 in total

1.  Biochemical Characterization and Computational Identification of Mycobacterium tuberculosis Pyrazinamidase in Some Pyrazinamide-Resistant Isolates of Iran.

Authors:  Farahnoosh Doustdar; Mohammad Pazhang; Faramarz Mehrnejad; Mehrnoosh Safarzadeh; Davod Rabiei; Nader Chaparzadeh; Hanieh Falahati; Mohammad Mir-Derikvand
Journal:  Protein J       Date:  2015-06       Impact factor: 2.371

2.  Comparison and development of pyrazinamide susceptibility testing methods for tuberculosis in Thailand.

Authors:  Suporn Foongladda; Wiphat Klayut; Suporn Pholwat; Eric Houpt
Journal:  Diagn Microbiol Infect Dis       Date:  2015-07-17       Impact factor: 2.803

3.  Acid-fast bacilli culture positivity and drug resistance in abdominal tuberculosis.

Authors:  Sora Yasri; Viroj Wiwanitkit
Journal:  Indian J Gastroenterol       Date:  2015-03

4.  Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance.

Authors:  Alessandro Mustazzolu; Angelo Iacobino; Federico Giannoni; Claudio Piersimoni; Lanfranco Fattorini
Journal:  J Clin Microbiol       Date:  2017-09-13       Impact factor: 5.948

5.  Improved Detection by Next-Generation Sequencing of Pyrazinamide Resistance in Mycobacterium tuberculosis Isolates.

Authors:  Nontuthuko E Maningi; Luke T Daum; John D Rodriguez; Matsie Mphahlele; Remco P H Peters; Gerald W Fischer; James P Chambers; P Bernard Fourie
Journal:  J Clin Microbiol       Date:  2015-09-16       Impact factor: 5.948

6.  Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium tuberculosis in New York City.

Authors:  Dawn Verdugo; Dorothy Fallows; Shama Ahuja; Neil Schluger; Barry Kreiswirth; Barun Mathema
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

7.  Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide.

Authors:  Zhenling Cui; Jie Wang; Junmei Lu; Xiaochen Huang; Ruijuan Zheng; Zhongyi Hu
Journal:  J Clin Microbiol       Date:  2013-02-06       Impact factor: 5.948

8.  Pyrazinamide susceptibility testing of Mycobacterium tuberculosis by high resolution melt analysis.

Authors:  Suporn Pholwat; Suzanne Stroup; Jean Gratz; Varittha Trangan; Suporn Foongladda; Happiness Kumburu; Saumu Pazia Juma; Gibson Kibiki; Eric Houpt
Journal:  Tuberculosis (Edinb)       Date:  2013-11-01       Impact factor: 3.131

9.  Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates.

Authors:  Simone Mok; Emma Roycroft; Peter R Flanagan; Lorraine Montgomery; Emanuele Borroni; Thomas R Rogers; Margaret M Fitzgibbon
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

10.  Antibiotic resistance prediction for Mycobacterium tuberculosis from genome sequence data with Mykrobe.

Authors:  Martin Hunt; Phelim Bradley; Simon Grandjean Lapierre; Simon Heys; Mark Thomsit; Michael B Hall; Kerri M Malone; Penelope Wintringer; Timothy M Walker; Daniela M Cirillo; Iñaki Comas; Maha R Farhat; Phillip Fowler; Jennifer Gardy; Nazir Ismail; Thomas A Kohl; Vanessa Mathys; Matthias Merker; Stefan Niemann; Shaheed Vally Omar; Vitali Sintchenko; Grace Smith; Dick van Soolingen; Philip Supply; Sabira Tahseen; Mark Wilcox; Irena Arandjelovic; Tim E A Peto; Derrick W Crook; Zamin Iqbal
Journal:  Wellcome Open Res       Date:  2019-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.